ClinicalTrials.gg
CompletedNCT00883727Updated Mar 5, 2013

Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI

A Phase 1/2 interventional study of Stem cell and Plasmalyte A in Myocardial Infarction, sponsored by Stempeutics Research Pvt Ltd. Completed at 4 sites in India. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-03-05.

Sponsored by Stempeutics Research Pvt Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Myocardial Infarction with a site in India — 1 open to participants now, 5 under way, 5 of them phase 3. Myocardial Infarction · India.

Enrollment
31st of 31
20 · median 3,712
Started
2009
with 1 other
Phase 1/2
2 of 35
none open now
Registered
15th of 35
by date

Among the 35 studies in Myocardial Infarction with a site in India, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1/2, and was the 15th registered.

Myocardial Infarction

2,272 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

1 of the 35 studies in Myocardial Infarction with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Myocardial Infarction with a site in India, or all of them as a file.
02

Study summary

This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • mesenchymal stem cells
  • myocardial infarction
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with STEMI aged between 20 and 70 years, either males or females with non-child bearing potential, after 2 days of successful PCI.
  • Patient has global left ventricular systolic dysfunction with an of \<50% and >30%.
  • with sign of acute anterior MI with ST-elevation ≥ 2 mm in at least 2 of the following leads I, AVL, V1-V6, or ECG with sign of acute inferoposterior MI with ST-elevation ≥1 mm on all of the following leads- II, III, V5-V6 or STelevation ≥ 2 mm in at least 2 of the leads.
  • The target lesion located in the proximal section of the left anterior descending, left circumflex or right coronary artery.
  • Patient with acute myocardial infarction within 10 days prior to IP administration.
  • Normal liver and renal function.
  • Able to understand study information provided to him.
  • Able to give voluntary written consent.

Exclusion criteria

Exclusion Criteria:

  • History of acute/chronic inflammatory condition or severe aortic stenosis or insufficiency; severe mitral stenosis or severe mitral insufficiency.
  • Severe co-morbidity associated with a reduction in of less than 1 year.
  • Advanced renal dysfunction and creatinine ≥ 2mg%.
  • Advanced hepatic dysfunction.
  • Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    stem cells

    Drug: Stem cell

  • Placebo comparator
    Placebo

    Drug: Plasmalyte A

Interventions

  • IV infusion of stem cells

  • DrugPlasmalyte A

    IV infusion

06

What researchers measure

Primary outcomes

  1. AE and ECG parameters

    Time frame: 6 months

Secondary outcomes

  1. Regional myocardial perfusion and infarct size

    Time frame: 6 months

07

Study locations

4 sites
  • Care Hospital
    Hyderabad, Andhra Pradesh 500034, India
  • SAL Hospital and Medical Institute
    Ahmedabad, Gujarat 380054, India
  • MS Ramaiah Memorial Hospital
    Bangalore, Karnataka 560054, India
  • Bhagawan Mahaveer Jain Heart Centre
    Bangalore, Karnataka 5660052, India
08

References and documents

Publications

  • Chullikana A, Majumdar AS, Gottipamula S, Krishnamurthy S, Kumar AS, Prakash VS, Gupta PK. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy. 2015 Mar;17(3):250-61. doi: 10.1016/j.jcyt.2014.10.009. Epub 2014 Dec 4. PubMed 25484310 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2009
First posted
Apr 20, 2009
Start
Apr 2009
Primary completionActual
May 2010
CompletionActual
Aug 2012
Last update
Mar 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00883727
Lead sponsor
Stempeutics Research Pvt Ltd
Responsible party
Sponsor
First posted
Apr 20, 2009
Start date
Apr 2009
Primary completion
May 2010
Completion
Aug 2012
Last update
Mar 5, 2013

Study contacts

Sreenivas Kumar, MD, DM
principal investigator · Care Hospital, Hyderabad
Satya Gupta
principal investigator · SAL Hospital, Ahmedabad
R Keshava, MD, DM
principal investigator · Bhagwan Mahaveer JAin Hospital, Bangalore
Prakash VS, MD., DM
principal investigator · MS Ramaiah Memorial Hospital, Bangalore

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion